Marc Rosen, MD
Otolaryngology · Philadelphia, PANPI 1023038718
Payments from drug & device makers
What this record shows
6 manufacturers reported payments, led by AstraZeneca at 59.5% of the total. Reporting peaked in 2024 at $2,194 and has fallen 88.3% since, to $257 in 2025.
Across 12 payments — averaging $263.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Stryker$380
- Medtronic$367
- Acclarent, Inc$260
- Regeneron$140
- Sanofi$133
Across 12 payments — averaging $4438.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$29K
- AstraZeneca$23K
- Genentech, Inc.$2K
What the payments were for
- Consulting fees$1,88059%
- Food & beverage$1,28041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $1,880 |
| Stryker | 3 | $380 |
| Medtronic | 2 | $367 |
| Acclarent, Inc | 4 | $260 |
| Regeneron | 1 | $140 |
| Sanofi | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$1,880
- SCOPIS ENT$281
- DUPIXENT$273
- NUVENT$250
- TruDi Nav Cable$176
- FUSION$117
How this compares
$3,159 in reported general payments places this provider in the 75th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 50 | $184,792 |
| Dupixent SyringeDupilumab | 11 | $41,888 |
| Ipratropium Bromide | 119 | $2,829 |
| Fluticasone Propionate | 98 | $1,148 |
| Doxycycline Monohydrate | 96 | $747 |
| Methylprednisolone | 75 | $449 |
| Montelukast Sodium | 20 | $356 |
| Mupirocin | 29 | $290 |
| Azelastine Hcl | 24 | $258 |
| Omeprazole | 19 | $187 |
| Ciprofloxacin Hcl | 24 | $182 |
| Prednisone | 59 | $181 |
| Famotidine | 19 | $118 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $92 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Philadelphia
- Nancy SnydermanPhiladelphia$4.5M
- David KennedyPhiladelphia$603K
- James PalmerPhiladelphia$331K
- Mathew NagorskyPhiladelphia$95K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
- Steven CannadyPhiladelphia$33K
- David CognettiPhiladelphia$30K
- John KrousePhiladelphia$30K
- Soo AbboudPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.